Fludarabine

Generic Name: Fludarabine

Brand Names: Fludara

Drug Type: Small Molecule

Chemical Formula: C_₁₀H_₁₂FN_₅O_₄

CAS Number: 21679-14-1

Unique Ingredient Identifier: P2K93U8740

Background: Fludarabine is a chemotherapeutic agent used in the treatment of hematological malignancies. It is commonly marketed under the brand name Fludara.

Indication: For the treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to or whose disease has progressed during treatment with at least one standard alkylating-agent containing regimen

Associated Conditions: B-cell chronic lymphocytic leukemia/prolymphocytic leukemia/small lymphocytic lymphoma refractory, Refractory Non-Hodgkin's lymphoma

Associated Therapies: -

Clinical Trials

Cloretazine (VNP40101M) With Hematopoietic Cell Transplantation for Hematologic Malignancies

Phase 1

Completed

Conditions: Hematologic Malignancies

Interventions: Drug: Cloretazine
Drug: Fludarabine

First Posted Date: 2007-08-28

Last Posted Date: 2012-07-31

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 5

Registration Number: NCT00521859

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Donor Stem Cell Transplant After Conditioning Therapy in Treating Patients With Hematologic Cancer, Recurrent or Metastatic Solid Tumor, or Other Disease

Not Applicable

Completed

Conditions: Nonmalignant Neoplasm
Multiple Myeloma and Plasma Cell Neoplasm
Lymphoma
Leukemia
Unspecified Adult Solid Tumor, Protocol Specific
Myelodysplastic Syndromes

First Posted Date: 2007-08-27

Last Posted Date: 2013-03-26

Lead Sponsor: Asan Medical Center

Target Recruit Count: 30

Registration Number: NCT00521430

Locations: 🇰🇷
Asan Medical Center - University of Ulsan College of Medicine, Seoul, Korea, Republic of

Early or Delayed Fludarabine and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia

Phase 3

Terminated

Conditions: Leukemia

Interventions: Biological: rituximab
Drug: fludarabine phosphate

First Posted Date: 2007-08-09

Last Posted Date: 2020-04-22

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 84

Registration Number: NCT00513747

Locations: 🇺🇸
Virginia K. Crosson Cancer Center at St. Jude Medical Center, Fullerton, California, United States
🇺🇸
Providence Saint Joseph Medical Center - Burbank, Burbank, California, United States
🇺🇸
Camino Medical Group - Treatment Center, Mountain View, California, United States

and more 379 locations

Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant

Phase 1

Completed

Conditions: Chronic Myeloproliferative Disorders
Graft Versus Host Disease
Leukemia
Lymphoma
Multiple Myeloma and Plasma Cell Neoplasm
Myelodysplastic Syndromes
Myelodysplastic/Myeloproliferative Neoplasms

Interventions: Drug: busulfan
Drug: cyclophosphamide
Drug: cyclosporin-A
Drug: etoposide
Drug: methotrexate
Drug: rasburicase
Drug: sirolimus
Procedure: allogeneic hematopoietic stem cell transplantation
Drug: tacrolimus
Procedure: peripheral blood stem cell transplantation
Radiation: total-body irradiation
Drug: fludarabine
Drug: allopurinol

First Posted Date: 2007-08-08

Last Posted Date: 2017-05-25

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 46

Registration Number: NCT00513474

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Phase II Study of Short-Term Cultured Anti-Tumor Autologous Lymphocytes After Lymphocyte-Depleting Chemotherapy in Metastatic Melanoma

Phase 2

Completed

Conditions: Melanoma
Malignant Melanoma
Melanoma, Experimental
Experimental Melanomas

Interventions: Biological: aldesleukin
Biological: therapeutic autologous lymphocytes
Drug: Cyclophosphamide
Drug: Fludarabine phosphate
Radiation: Total body irradiation

First Posted Date: 2007-08-08

Last Posted Date: 2013-06-03

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 158

Registration Number: NCT00513604

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Bortezomib (Velcade) With Standard Chemotherapy for Relapsed or Refractory Follicular Lymphoma

Phase 2

Terminated

Conditions: Lymphoma, Follicular

Interventions: Drug: Bortezomib
Drug: Rituximab
Drug: Fludarabine
Drug: Mitoxantrone
Drug: Dexamethasone

First Posted Date: 2007-08-02

Last Posted Date: 2014-05-12

Lead Sponsor: Duke University

Target Recruit Count: 14

Registration Number: NCT00510887

Locations: 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States

Phase II Study of Metastatic Melanoma With Lymphodepleting Conditioning and Anti-gp100:154-162 TCR Gene Engineered Lymphocytes

Phase 2

Terminated

Conditions: Skin Cancer
Melanoma

Interventions: Drug: fludarabine phosphate
Drug: cyclophosphamide
Biological: aldesleukin

First Posted Date: 2007-07-31

Last Posted Date: 2013-01-15

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 21

Registration Number: NCT00509496

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Phase II Study of Metastatic Melanoma With Lymphodepleting Conditioning and Infusion of Anti-MART-1 F5 TCR-Gene-Engineered Lymphocytes

Phase 2

Completed

Conditions: Melanoma
Skin Cancer

Interventions: Biological: autologous anti-MART-1 F5 T-cell receptor
Drug: Cyclophosphamide
Drug: Fludarabine
Biological: Aldesleukin
Biological: autologous anti-MART-1 F5 T-cell receptor gene-engineered tumor infiltrating lymphocytes

First Posted Date: 2007-07-31

Last Posted Date: 2012-12-28

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 24

Registration Number: NCT00509288

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Phase I/II Trial of Fludarabine Plus Busulfan and Allogeneic Progenitor Cell Support

Phase 1

Completed

Conditions: Hematologic Malignancies

Interventions: Drug: Busulfan
Drug: Fludarabine

First Posted Date: 2007-07-25

Last Posted Date: 2012-02-28

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 82

Registration Number: NCT00506857

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Autologous and Allogenic Transplantation With Campath-1H for T-Cell Lymphoma

Phase 2

Terminated

Conditions: Lymphoma

Interventions: Drug: Campath-1H
Drug: G-CSF
Drug: GM-CSF
Drug: BCNU
Drug: Stem Cell Transplant
Drug: Preparative Regimen for Allogenic Stem Cell Transplantation
Drug: Cytarabine
Drug: Etoposide
Drug: Melphalan
Drug: Campath
Drug: Fludarabine
Drug: Cyclophosphamide
Radiation: Low dose total body irradiation

First Posted Date: 2007-07-25

Last Posted Date: 2011-11-16

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 27

Registration Number: NCT00505921

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy